Apteeus is a Biotech company specialized in drug discovery and repositioning. With R&D capabilities within Pasteur Institute in Lille, it brings together a team of researchers whose objective is to quickly respond to unmet medical needs. His area of expertise covers a large number of diseases, including rare monogenic diseases, particularly inherited metabolic disorders and genodermatoses. Whenever the cause of the disease can be measured in cultured patient cells, the team is committed to testing in vitro the effect of all existing drugs in a couple of months.

Apteeus is aiming at delivering disease modifying, first in class therapies to patients through accelerated development and strong scientific rational. Concerned about reconciling the time of research with that of medicine, our first approach is based on the repositioning of molecules approved in humans. The team’s objectives are to respond quickly to the medical needs of patients by identifying new avenues of treatment. Motivated by science, medicine and pharmacy, we involve patients in finding their own treatment and systematically consider compassionate use of drugs in parallel of new drug development.

The technological competitive advantages associated with Apteeus’ development models are a complete break with the classic pharmaceutical R&D scheme and make Apteeus a pioneer in Europe in providing economically viable solutions for the therapeutic management of rare monogenic diseases. Apteeus aims for a rapid and significant social impact in the field of rare and orphan diseases.